Correlation of SOZO BIS Measures With CardioMEMS PA Pressure

Sponsor
ImpediMed Limited (Industry)
Overall Status
Completed
CT.gov ID
NCT02939053
Collaborator
Baim Institute for Clinical Research (Other), Scripps Health (Other)
3
2
21.8
1.5
0.1

Study Details

Study Description

Brief Summary

This study aims to establish the degree to which change in the ratio of ECF to TBW measured using the SOZO BIS device correlates with change in end-expiratory end-diastolic PAP measured using the CardioMEMS HF System (St. Jude Medical).

Condition or Disease Intervention/Treatment Phase
  • Device: SOZO

Detailed Description

This is a prospective, single-arm, observational, non-randomized clinical study that will enroll patients with heart failure who have had a CardioMEMS™ device implanted to monitor their diastolic pulmonary artery pressure. The study will recruit and enroll thirty participants. Participants will be monitored daily at home for a period of 30 days. Each day, the patient's diastolic pulmonary artery pressure will be measured by CardioMEMS™ and the ImpediMed's BIS technology. Participant's weight will also be taken each day.

Study Design

Study Type:
Observational
Actual Enrollment :
3 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Correlation of Bioimpedance Measurements From the SOZO Device With Pulmonary Arterial Pressure Measurements From the CardioMEMS HF System
Actual Study Start Date :
Aug 29, 2017
Actual Primary Completion Date :
May 3, 2018
Actual Study Completion Date :
Jun 25, 2019

Arms and Interventions

Arm Intervention/Treatment
Single-arm

All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.

Device: SOZO
The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.

Outcome Measures

Primary Outcome Measures

  1. Change in the ratio of whole body ECF/TBW measured using the SOZO BIS device [From baseline through study completion, an average of 30 days]

    Changes of body fluid levels in heart failure patients

Secondary Outcome Measures

  1. Change in the ratio of thoracic ECF/TBW [From baseline through study completion, an average of 30 days]

    Changes of thoracic fluid levels in heart failure patients

  2. Change in the ratio of lower extremity ECF/TBW [From baseline through study completion, an average of 30 days]

    Changes of lower limb fluid levels in heart failure patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 18 years or older.

  2. NYHA Class III HF.

  3. Patient has undergone implantation of CardioMEMS HF System (St. Jude Medical).

  4. Patient is characterized by at least one of the following:

  • CardioMEMS implanted within the previous 90 days

  • Received treatment with intravenous diuretics within the previous 30 days

  • Received dose escalation of oral diuretics at least twice within the previous 30 days

  1. Patient is able to sit upright for BIS measurements.

  2. Patient provides written informed consent and authorization to use and disclose health information.

Exclusion Criteria:
  1. Patient is enrolled in a concurrent interventional study of an experimental treatment that may confound the results of this study, in the investigator's opinion.

  2. Patient has a clinical condition that would not allow them to complete the study.

  3. Patient is pregnant or lactating.

  4. Patient has nephrotic syndrome or nephrosis.

  5. Patient has estimated glomerular filtration rate (eGFR) < 20 ml/min/1.73m2 or end-stage renal disease requiring chronic dialysis.

  6. Patient has been diagnosed with lymphedema.

  7. Patient has chronic liver failure or cirrhosis.

  8. Patient has a moderate or large pleural effusion as seen on chest X-ray.

  9. Patient has been diagnosed with thrombophlebitis or deep vein thrombosis in arms or legs in the past 90 days.

  10. Patient has an implanted cardiac rhythm management device (pacemaker or implantable cardioverter defibrillator).

  11. Patient has an amputation of a limb.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic Rochester Minnesota United States 55905
2 Lancaster General Hospital Lancaster Pennsylvania United States 17603

Sponsors and Collaborators

  • ImpediMed Limited
  • Baim Institute for Clinical Research
  • Scripps Health

Investigators

  • Principal Investigator: Roy Small, MD, Lancaster General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ImpediMed Limited
ClinicalTrials.gov Identifier:
NCT02939053
Other Study ID Numbers:
  • IPD-SOZO-01
First Posted:
Oct 19, 2016
Last Update Posted:
Jul 8, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by ImpediMed Limited
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 8, 2019